Ola Vedin
Overview
Explore the profile of Ola Vedin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
1131
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Harrington J, Udell J, Jones W, Anker S, Bhatt D, Petrie M, et al.
Am Heart J
. 2022 May;
253:86-98.
PMID: 35595091
Background: Patients with acute myocardial infarction (MI) are at risk for developing heart failure (HF) and subsequently are at an increased risk of mortality. Sodium-glucose cotransporter-2 inhibitors have been proven...
12.
Anker S, Sander L, Fitchett D, Zinman B, Ofstad A, Wanner C, et al.
Diabetes Res Clin Pract
. 2022 Mar;
186:109837.
PMID: 35314257
Aims: Type 2 diabetes mellitus (T2DM) and chronic obstructive pulmonary disease (COPD) often co-exist, yielding increased risk of cardiovascular (CV) complications including heart failure (HF). We assessed risk of cardiorenal...
13.
Butler J, Filippatos G, Siddiqi T, Brueckmann M, Bohm M, Chopra V, et al.
Circulation
. 2021 Nov;
145(3):184-193.
PMID: 34779658
Background: Patients with heart failure with preserved ejection fraction have significant impairment in health-related quality of life. In the EMPEROR-Preserved trial (Empagliflozin Outcome Trial in Patients With Chronic Heart Failure...
14.
Januzzi Jr J, Zannad F, Anker S, Butler J, Filippatos G, Pocock S, et al.
J Am Coll Cardiol
. 2021 Sep;
78(13):1321-1332.
PMID: 34556318
Background: The relationship between the benefits of empagliflozin in heart failure with reduced ejection fraction (HFrEF) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) has not been reported. Objectives: The authors sought...
15.
Savarese G, Uijl A, Lund L, Anker S, Asselbergs F, Fitchett D, et al.
J Card Fail
. 2021 Aug;
27(8):888-895.
PMID: 34364665
Background: In the EMPA-REG OUTCOME trial, ejection fraction (EF) data were not collected. In the subpopulation with heart failure (HF), we applied a new predictive model for EF to determine...
16.
Thomsen R, Knudsen J, Kahlert J, Baggesen L, Lajer M, Holmgaard P, et al.
J Am Heart Assoc
. 2021 May;
10(11):e019356.
PMID: 34032121
Background In cardiovascular outcome trials, the sodium glucose cotransporter 2 inhibitor empagliflozin and glucagon-like peptide-1 (GLP-1) receptor agonist liraglutide caused similar reductions in major adverse cardiac events (MACE). We compared...
17.
Butler J, Anker S, Filippatos G, Khan M, Ferreira J, Pocock S, et al.
Eur Heart J
. 2021 Jan;
42(13):1203-1212.
PMID: 33420498
Aims: In this secondary analysis of the EMPEROR-Reduced trial, we sought to evaluate whether the benefits of empagliflozin varied by baseline health status and how empagliflozin impacted patient-reported outcomes in...
18.
Fu M, Vedin O, Svennblad B, Lampa E, Johansson D, Dahlstrom U, et al.
ESC Heart Fail
. 2020 Sep;
7(6):3633-3643.
PMID: 32881399
Aims: The aim of this study is to study the introduction of sacubitril/valsartan (sac/val) in Sweden with regards to regional differences, clinical characteristics, titration patterns, and determinants of use and...
19.
Rosengren S, Clemmensen T, Tolbod L, Granstam S, Eiskjaer H, Wikstrom G, et al.
JACC Cardiovasc Imaging
. 2020 May;
13(6):1337-1347.
PMID: 32417330
Objectives: This dual-site study evaluated the diagnostic accuracy of the method. Background: Pittsburgh compound ([C]PIB) positron emission tomography (PIB-PET) has shown promise as a specific and noninvasive method for the...
20.
Savarese G, Settergren C, Schrage B, Thorvaldsen T, Lofman I, Sartipy U, et al.
Int J Cardiol
. 2020 May;
313:76-82.
PMID: 32360702
Background: Comorbidities may differently affect treatment response and cause-specific outcomes in heart failure (HF) with preserved (HFpEF) vs. mid-range/mildly-reduced (HFmrEF) vs. reduced (HFrEF) ejection fraction (EF), complicating trial design. In...